The EORTC Ophthalmic Oncology Quality of Life Questionnaire Module (EORTC QLQ-OPT30). Development and Pre-Testing (Phase I-III)

Brandberg, Yvonne; Damato, Bertil; Kivelä, Tero; Kock, Erik; Seregard, Stefan

doi:10.1038/sj.eye.6700639

Cited by 38 publications

(35 citation statements)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ninety-eight patients with UM treated with radiotherapy approximately 3 years before entering the study returned the questionnaires. Three areas were investigated: (a) QoL assessed with a visual analogue scale (VAS) administered before and after treatment; (b) physical symptoms and treatment side effects, measured with the EORTC QLQ-C30 and the EORTC QLQ-OPT30 questionnaires; (c) anxiety and depression signs and symptoms as a result of the psychological effects of illness and of the side-effects of therapy, measured with the Hospital Anxiety and Depression Scale (HADS) [31]. The level of QoL as individually experienced reached a mean of 74.1% before therapy and a mean of 69% after therapy, indicating a limited decline (5%), as confirmed by the EORTC-QLQ-OPT37 scores.…”

Section: Resultsmentioning

confidence: 99%

Quality of Life, Depression, and Anxiety in Patients with Uveal Melanoma: A Review

Fabrini

Ebert

Mancino

et al. 2018

Journal of Oncology

View full text Add to dashboard Cite

The aim is to summarize current knowledge on both QoL and depressive/anxious symptoms in patients with UM, including studies on the effect on QoL and psychological status of genetic testing related to the risk of metastatic disease. A review from the last 25 years by using the databases “PsycInfo,” “Medline,” and “Science Direct” was performed. As a total result, eighteen papers were retrieved. Eight studies (44.4%) used a prospective design methodology: two were retrospective observations (11.1%), three were cross-sectional observational studies (16.6%), and three (16.6%) were naturalistic follow-up studies. One trial was conducted with a case-control design (5.5%), and one was a methodological paper (5.5%). The number of subjects included in the studies ranged widely, between 7 and 842 (mean: 152.1 ± 201.3), for a total of 2587 patients, 1306 males (50.5%) and 1281 females (49.5%). The mean age of subject enrolled was 61.3 ± 4.1 years. Twenty-six different scales, questionnaires, or interviews were utilized. No significant differences in QoL between radiotherapy and enucleation emerged. Genetic testing did not significantly affect QoL or psychological status.

show abstract

Section: Resultsmentioning

confidence: 99%

Quality of Life, Depression, and Anxiety in Patients with Uveal Melanoma: A Review

Fabrini

Ebert

Mancino

et al. 2018

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…However, after four years we found a lower Global health score for patients with metastases (71) versus without metastases (78). Unfortunately, the EORTC ophthalmic Oncology Quality of Life Questionnaire Module (EORTC QLQ-OPT30), an extra questionnaire module more specific for quality of life in uveal melanoma patients, was published 5 years after we started our study, and was not available at that moment (Brandberg et al 2004). The normative data for the EORTC QLQ-C30 in the general Dutch population shows an overall mean score of Global quality of life of 78 (SD: 17) for men (n = 935) and 77 (SD: 18) for women (n = 796) (van de Poll-Franse et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients

Beek

Buitendijk

Timman³

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose: To report the quality of life and visual functioning in uveal melanoma patients treated with enucleation or fractionated stereotactic radiation therapy (fSRT).Methods: Uveal melanoma (UM) patients treated with fSRT (n = 65) or enucleation (n = 48) participated in this prospective study. Questionnaires to measure anxiety (State-Trait Anxiety Inventory), subjective distress (Impact of Event Scale) and quality of life (EORTC-QLQ-C30 and National Eye Institute Visual Function Questionnaire (VFQ-25)) were obtained before treatment and 2, 6, 12, 24, 36 and 48 months after treatment.Results: Less peripheral vision was observed until 3 years (p = 0.026) posttreatment in enucleated patients compared to irradiated patients. From 2 months until 3 years posttreatment irradiated patients increase in role functioning-score (p = 0.005), while enucleated patients decrease in score (p = 0.012). Regardless of their treatment, for all patients we measured a reduction in physical functioning (p = 0.035), insomnia (p < 0.001) and in state anxiety from pretreatment until 2 years posttreatment (p < 0.001). An increase in pain overall (p = 0.023) and in emotional functioning is observed 1 year posttreatment (p < 0.001). At baseline, patients with metastases (independent of their treatment) have more subjective distress (p = 0.037) than patients without metastases. The mean 'global health score' overall, without effect of time, was 76.4 (SD: 13.6).Conclusion: Enucleated patients had more difficulty working or performing household tasks 2 months posttreatment compared to irradiated patients. Enucleated patients had diminished peripheral vision until 3 years compared to irradiated patients. Overall quality of life is not significantly different between both treatment groups.

show abstract

“…Loss of vision and the ability to drive a car in particular have a huge impact on quality of life [26]. As preservation of binocular vision and stereopsis is considered to be of great importance for a good quality of life, we included a subgroup analysis with patients who had a final BCVA of 0.5 log(MAR) or higher.…”

Section: No Glaucoma Glaucomamentioning

confidence: 99%

“…Yet, compared with the SF-12 survey, this may exceed the recommended maximum of 30 items [29], needing more time and concentration for fulfillment. Additional questionnaires have to be used in conjunction with the core questionnaire [26] possibly influencing the patients' compliance.…”

Section: No Glaucoma Glaucomamentioning

confidence: 99%

“…The survey was specifically developed to assess the quality of life of cancer patients. The EORTC QLQ-OPT30 module consists of 30 items for uveal melanoma patients receiving treatments other than enucleation [26]. Melanoma-associated or treatment-associated symptoms such as irritation, visual impairment, headache, worry about recurrent disease, problems with driving, problems with appearance, functional problems because of visual impairment, and reading problems can be assessed [26].…”

Section: No Glaucoma Glaucomamentioning

confidence: 99%

See 1 more Smart Citation

Quality of life in the follow-up of uveal melanoma patients after CyberKnife treatment

Klingenstein¹,

Fürweger²,

Nentwich³

et al. 2013

Melanoma Research

View full text Add to dashboard Cite

To assess quality of life in uveal melanoma patients within the first and second year after CyberKnife radiosurgery. Overall, 91 uveal melanoma patients were evaluated for quality of life through the Short-form (SF-12) Health Survey at baseline and at every follow-up visit over 2 years after CyberKnife radiosurgery. Statistical analysis was carried out using SF Health Outcomes Scoring Software and included subgroup analysis of patients developing secondary glaucoma and of patients maintaining a best corrected visual acuity (BCVA) of the treated eye of 0.5 log(MAR) or better. Analysis of variance, GreenhouseGeisser correction, Student's t-test, and Fisher's exact test were used to determine statistical significance. Physical Functioning (PF) and Role Physical (RP) showed a significant decrease after CyberKnife radiosurgery, whereas Mental Health (MH) improved (P = 0.007, P < 0.0001 and P = 0.023). MH and Social Functioning (SF) increased significantly (P = 0.0003 and 0.026) in the no glaucoma group, MH being higher compared with glaucoma patients (P = 0.02). PF and RP were significantly higher in patients with higher BCVA at the second followup (P = 0.02). RP decreased in patients with BCVA < 0.5 log(MAR) (P = 0.013). Vitality (VT) increased significantly in patients whose BCVA could be preserved (P = 0.031). Neither tumor localization nor size influenced the development of secondary glaucoma or change in BCVA. Although PF and RP decreased over time, MH improved continuously. Prevention of secondary glaucoma has a significant influence on both SF and MH, whereas preservation of BCVA affects VT. Emotional stability throughout follow-up contributes positively toward overall quality of life. CyberKnife radiosurgery may contribute to attenuation of emotional distress in uveal melanoma patients.

show abstract

The EORTC Ophthalmic Oncology Quality of Life Questionnaire Module (EORTC QLQ-OPT30). Development and Pre-Testing (Phase I-III)

Cited by 38 publications

References 17 publications

Quality of Life, Depression, and Anxiety in Patients with Uveal Melanoma: A Review

Quality of Life, Depression, and Anxiety in Patients with Uveal Melanoma: A Review

Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients

Quality of life in the follow-up of uveal melanoma patients after CyberKnife treatment

Contact Info

Product

Resources

About